Novo Nordisk AS (OCSE:NOVO B)
kr 757.3 9.7 (1.3%) Market Cap: 3.36 Til Enterprise Value: 3.35 Til PE Ratio: 35.72 PB Ratio: 27.97 GF Score: 97/100

Q2 2019 Novo Nordisk A/S Earnings Call Transcript

Aug 09, 2019 / 11:00AM GMT
Release Date Price: kr167 (-0.24%)
Operator

Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to today's Q2 2019, Novo Nordisk AS Earnings Conference Call. (Operator Instructions) This conference is being recorded today, Friday 9 of August 2019.

I would now like to hand the conference over to your speaker today, Lars Fruergaard Jørgensen, the CEO. Please go ahead, sir.

Lars Fruergaard JÃ;rgensen;S;President;CEO
Novo Nordisk A

¸ - /-&

Thank you very much. Welcome to this Novo Nordisk conference call regarding our performance in the first 6 months of 2019 and our performance -- sorry, our outlook for the year.

I'm Lars Fruergaard Jørgensen, the CEO of Novo Nordisk. With me I have our Chief Financial Officer, Karsten Knudsen; and our Chief Science Officer, Mads Krogsgaard Thomsen.

Today's earnings release and the slides for this call are available on our website, novonordisk.com. The call is scheduled to last for 1 hour. The presentation is structured as outlined on Slide 2, please note

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot